Please login to the form below

Not currently logged in
Email:
Password:

ASH 2018

This page shows the latest ASH 2018 news and features for those working in and with pharma, biotech and healthcare.

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

new data at the ASH 2018 congress in multiple myeloma. ... Amgen also reported data at ASH on another BiTE candidate called AMG 330 which targets CD33, the same target as Regeneron’s REGN1979 which posted results in lymphoma earlier during the

Latest news

  • Regeneron’s early stage bispecific shows promise Regeneron’s early stage bispecific shows promise

    Regeneron is one many companies developing bispecifics, and on Saturday at the ASH 2018 congress in San Diego, unveiled phase 1 proof of concept data for its REGN1979 in relapsed or ... Also presenting bispecific antibodies at ASH are Amgen (AMG 420) and

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    The ASH congress is the most comprehensive haematology event of the year, over 5000 abstracts covering new developments in malignant and non-malignant haematology were presented. ... If you would like to discuss insights from ASH 2018 or have any

  • Porterhouse Medical Group

    Highlights in haematologic malignancy from ASH 2018. ... To support World AIDS Day 2018 and to help tackle the stigma surrounding the condition, Porterhouse Medical explores the misconceptions surrounding HIV/AIDS.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics